Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 4, April, p. 489–498

doi: 10.17219/acem/78688

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The journey of the heart failure patient, based on data from a single center

Anna Chuda1,B,C,D, Joanna Berner1,B,C,D, Małgorzata Lelonek1,A,E,F

1 Department of Noninvasive Cardiology, Chair of Internal Medicine and Cardiology, Medical University of Lodz, Poland

Abstract

Background. Care for patients with heart failure (HF) in Poland requires improvement.
Objectives. The aim of this study was to define the journey of the HF patient, taking into account the specialization of the hospital ward and further, highly specialized outpatient care.
Material and Methods. Using the medical system CliniNET®, we analyzed 214 consecutive patients hospitalized due to HF (International Statistical Classification of Diseases and Health Related Problems – ICD-10: I50) in the period from September 1 to December 31, 2015, and also the data from post-discharge outpatient care in a 3-month period. To fairly compare the management of care and outcomes of patients hospitalized in the internal medicine (IM) ward and in the cardiac ward, propensity score matching was performed. The multivariate regression analysis was performed to determine the independent predictors of the hospital ward selection and the risk of rehospitalization due to HF and/or death.
Results. The majority of patients were hospitalized due to HF for the first time (72%) and in the cardiac ward (65%). For 55% of rehospitalized patients, the subsequent admission was within 3 months after initial discharge. The independent predictors of a higher risk of rehospitalization due to HF and/or death were ischemic heart disease, atrial fibrillation (AF), chronic kidney disease (CKD), mineralocorticoid antagonism (MRA) therapy, and hospitalization in the last year (for all, p < 0.05). Internal medicine ward patients differed from cardiac ward patients in: mode of admission (urgent 100% vs 83.5%; p < 0.001), length of hospitalization (median: 8 days vs 5 days; p = 0.001), death rate (24% vs 4.3%; p < 0.001), echocardiography (43% vs 98%; p < 0.001), and N-terminal prohormone B-type natriuretic peptide (NT-proBNP) measurements (43% vs 96%; p < 0.001). The burden of 5–9 accompanying diseases enhanced the choice of the cardiac ward (p < 0.05), while age and urgent mode of hospitalization decreased the chance of being referred to the cardiac ward (p < 0.01). Cardiac patients were more likely to receive β-blockers, diuretics, angiotensin receptor blockers (ARB), and MRA. Over 90% of cardiac ward patients were referred to cardiac ambulatory care after discharge from hospital, while among patients discharged from the IM ward, this rate was 60% (p < 0.001).
Conclusion. There were significant differences among the 2 wards in relation to the course of hospitalization and post-discharge outpatient care.

Key words

heart failure, hospitalization, cardiology, internal medicine

References (31)

  1. Ponikowski P, Voors A, Anker S, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129–2200.
  2. OECD. Health at a Glance 2015. OECD Indicators. 2015. doi: 10.1787/health_glance-2015-en
  3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–1146.
  4. Mozaffarian D, Benjamin EJ, Go AS, et al.; American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2016 update: A report from the American Heart Association. Circulation. 2016;133(4):e38–360.
  5. Lloyd-Jones DM, Larson MG, Leip EP, et al.; Framingham Heart Study. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. Circulation. 2002;106(24):3068–3072.
  6. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297(1):61–70.
  7. Dharmarajan K, Hsieh AF, Lin Z, et al.; OPTIMIZE-HF Investigators and Hospitals. Diagnosis and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355–363.
  8. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: Problems and perspectives. J Am Coll Cardiol. 2013;61(4):391–403.
  9. Maggioni AP, Dahlstrom U, Filippatos G, et al.; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;15(7):808–817.
  10. Solomon SD, Dobson J, Pocock S, et al.; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482–1487.
  11. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2012 update: A report from the American Heart Association. Circulation. 2012;125(1):e2–e220.
  12. Fonarow GC, Stough WG, Abraham WT, et al.; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):767–768.
  13. Gierczyński J, Gryglewicz J, Karczewicz E, Zalewska H. Heart Failure – Analysis of the Economic and Social Costs. Warszawa, Poland: Instytut Zarządzania w Ochronie Zdrowia Uczelni Łazarskiego w Warszawie; 2013.
  14. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA: Little Brown & Co.; 1994:253–256.
  15. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.
  16. Kolh P, Windecker S, Alfonso P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517–592.
  17. McMurray JJ, Adamopoulos S, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  18. Brignole M, Auricchio A, Baron-Esquivias G, et al.; 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15(8):1070–1118.
  19. Garcia Castelo A, Muniz Garcia J, Sesma Sanches P, Castro Beiras A; Grupo de estudio INCARGAL. Use of diagnostic and therapeutic resources in patients hospitalized for heart failure: Influence of admission ward type (INCARGAL Study) [in Spanish]. Rev Esp Cardiol. 2003;56(1):49–56.
  20. Bellotti P, Badano LP, Acquarone N, et al.; OSCUR Investigators. Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Oucome dello Scompenso Cardiaco in relazione all’Utilizzo delle Risore. Eur Heart J. 2001;22(7):596–604.
  21. Di Lenarda A, Scherillo M, Maggioni AP, et al.; TEMISTOCLE Investigators. Current presentation and management of heart failure in cardiology and internal medicine hospital units: A tale of 2 worlds – the TEMISTOCLE study. Am Heart J. 2003;146(4):E12.
  22. Petrovic V, Sirar I, Valerie AP. A tale of two specialties: Differences between heart failure patients admitted to internal medicine and cardiology. Can J Gen Intern Med. 2013;8 (1):4–7.
  23. Wojtczak-Soska K, Sakowicz A, Pietrucha T, Lelonek M. Soluble ST2 protein in the short-term prognosis after hospitalization in chronic systolic heart failure. Kardiol Pol. 2014;72(8):725–734.
  24. Lelonek M. Heart failure and rehospitalization [in Polish]. Folia Cardiol. 2016;11(1):37–46.
  25. Cichocka-Radwan A, Lelonek M. Annual prognostic factors in chronic heart failure in patients over 80 years old. Kardiol Pol. 2017;75:164–173.
  26. Solnica B. Biomarkers in heart failure: Ready for use? Pol Arch Med Wewn. 2015;125(6):398–399.
  27. Maggioni AP, Dahlstrom U, Filippatos G, et al.; Heart Failure Association of ESC (HFA). EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12(10):1076–1084.
  28. Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: An analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail. 2014;16(1):103–111.
  29. Sosnowska-Pasiarska B, Bartkowiak R, Wożakowska-Kapłon B, et al. Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). Kardiol Pol. 2013;71(3):234–240.
  30. Komajda M, Anker S, Cowie M, et al.; QUALIFY Investigators. Physician’s adherence to guideline-recommended medications in heart failure with reduced ejection fraction: Data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514–522.
  31. Swedberg K, Komajda M, Bohm M, et al.; SHIFT Investigators. Iva-bradine and outcomes in chronic heart failure (SHIFT): A randomized placebo-controlled study. Lancet. 2010;376(9744):875–885.
© Wroclaw Medical University